Strategic Collaboration Target potential co-development and joint venture opportunities with Empirico’s Precision Insights Platform and siRCH platform to accelerate target discovery and siRNA therapeutic development, leveraging their established partnerships such as with AbCellera.

Antisense to siRNA Position complementary antisense and siRNA modality offerings to Empirico as part of a broader portfolio, given their focus on siRNA medicines and historically noted antisense therapeutic work through Ionis collaborations.

Expansion Readiness Highlight capabilities and capacity for scaling through their multi-site footprint (San Diego and Madison) to support additional discovery, validation, or early‑stage clinical programs, aligning with potential licensing, sponsored research, or collaborative development deals.

Financial Leverage Leverage Empirico’s sizeable funding and revenue range to pursue high-value partnerships, upfronts, and milestone structures, emphasizing risk-sharing models aligned with their late-stage discovery and early clinical development timelines.

Technology Synergy Offer technology integrations, data collaboration, and cloud-based computational biology support (Azure, Linux, data tools) to enhance their Precision Insights and siRCH platforms, appealing to their data-driven target discovery and rapid program progression.